The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia
Open accessAbstract
The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA Receptor Hypofunctioning Hypothesis of Schizophrenia. The latter hypothesis may actually be the starting point in neuronal pathways that ultimately modifies dopamine pathways involved in generating both positive and negative symptoms of schizophrenia postulated by the former hypothesis. The authors suggest that even this latter, NMDA receptor-based, hypothesis is likely too narrow and offer a review of typical glutamate and dopamine-based neurocircuitry, propose genetic vulnerabilities impacting glutamate neurocircuitry, and provide a broad interpretation of a possible etiology of schizophrenia. In conclusion, there is a brief review of potential schizophrenia treatments that rely on the etiologic theory provided in the body of the paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular cloning and characterization of the rat NMDA receptor
Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1991) · Nature · doi:10.1038/354031a0 · Cited by 1,771 · cited 1×
“In this manner, NMDA receptors with different functional capacities may be situated in the brain in order to make neurocircuits more, or less active (Moriyoshi et al., 1991; Hollmann and Heinemann, 1994; Nakanishi and Masu, 1994).”
BackgroundMice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Neurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298 · cited 2×
“…more advanced, neuroscience or neuroanatomic reader, this simple theoretical material may be made more complex by reviewing the extensive work by Carlsson et al. (1999) and the following figures may represent the greater complexity of the neuroanatomic basis of the dopaminergic and…”
BackgroundKinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256 · cited 1×
“The placebo rate was quite high for a schizophrenia study and four subjects suffered seizure-like activity (Kinon et al., 2011).”
BackgroundBegni, S., Popoli, M., Moraschi, S., Bignotti, S., Tura, G. B., & Gennarelli, M. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000987 · Cited by 71 · cited 1×
“The non-NMDA ionotropic glutamate receptor kainate-3 gene (GRIK3) codes for glutamate kainite receptors and certain mutations here may pose a possible risk for schizophrenia (Begni et al., 2002).”
Background
Cited by
Moving Forward: Challenges and Directions for Psychopathological Network Theory and Methodology
Fried, E. I., & Cramer, A. O. J. (2017) · Perspectives on Psychological Science · doi:10.1177/1745691617705892 · Cited by 938
Barth, C., Villringer, A., & Sacher, J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00037 · Cited by 711
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
The nature of relapse in schizophrenia
Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-50 · Cited by 478
Fried, E. I. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00309 · Cited by 367
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 289
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Lieberman, J. A., Davis, R. E., Correll, C. U., Goff, D. C., Kane, J. M., Tamminga, C. A., Mates, S., & Vanover, K. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.026 · Cited by 261
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
The Role of Cytokines in the Pathogenesis of Schizophrenia
Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173849 · Cited by 102
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89
Gleich, T., Deserno, L., Lorenz, R. C., Boehme, R., Pankow, A., Buchert, R., Kuhn, S., Heinz, A., Schlagenhauf, F., & Gallinat, J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0329-15.2015 · Cited by 62
“With respect to local glutamate, the VS receives direct excitatory glutamatergic input, particularly from the hippocampus and amygdala (Grace, 1991; Sesack et al., 2003; Schwartz et al., 2012).”
BackgroundIntrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“FIGURE 1 | Glutamatergic circuitry of the human brain: five cortical pathways (35, 36).”
BackgroundGranseth, B., Andersson, F. K., & Lindström, S. H. (2015) · Genes, Brain and Behavior · doi:10.1111/gbb.12230 · Cited by 23
“propose in a model that integrates glutamate and dopamine signaling in the etiology of schizophrenia (Schwartz et al. 2012).”
BackgroundDawidowski, B., Grelecki, G., Biłgorajski, A., Podwalski, P., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010232 · Cited by 22
Immune markers of social cognitive bias in schizophrenia
Dunne, P. W., Roberts, D. L., Quinones, M. P., Velligan, D. I., Paredes, M., & Walss-Bass, C. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.030 · Cited by 12
Metadata
- Authors
- Schwartz, T. L., Sachdeva, S., & Stahl, S. M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 195-195
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W1987248281
- Cited by
- 187
- References
- 7
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.